Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 10 Oct 2012 |
| Grant of Warrants to Employees in Genmab | 9 Oct 2012 |
| Agreement for Daratumumab Receives Antitrust Clearance | 21 Sept 2012 |
| Genmab Enters Worldwide Agreement with Janssen for Daratumumab | 30 Aug 2012 |
| Additional details concerning issue of shares to Johnson & Johnson Development Corporation as part of the daratumumab agreement | 30 Aug 2012 |